Know Labs Stock Price, News & Analysis

Know Labs, Inc. (traded over-the-counter under the symbol KNWND during the period referenced in the news items) is focused on developing and licensing a platform technology based on Radio Frequency Dielectric Spectroscopy (RFDS). According to the company, this RFDS sensor technology directs electromagnetic energy through a substance or material to capture a unique molecular signature. Know Labs states that its patented and patent-pending RFDS technology is designed to integrate into various wearable, mobile, or bench-top form factors.

The company believes this approach can enable the identification and monitoring of analytes that previously required invasive and/or expensive and time-consuming laboratory tests. Among its first expected applications, Know Labs highlights a product that it plans to market as a non-invasive glucose monitor. This device is described as being designed to provide users with accessible and affordable real-time information on blood glucose levels. The company notes that this product will require clearance from the U.S. Food and Drug Administration (FDA) before it can be introduced to the market.

Beyond its initial medical application focus, Know Labs emphasizes the breadth of its intellectual property. The company has reported a portfolio of issued, pending, and in-process patents, along with a large number of codified trade secrets. It describes its intellectual property as covering core elements of how its RFDS technology works and potential applications across diverse industries and fields of use. Know Labs states that it has built this portfolio in a strategic manner, grounded on what it describes as first principles of physics.

Know Labs Technology Licensing (KTL)

Know Labs has established Know Labs Technology Licensing (KTL) as a dedicated licensing division. According to the company, KTL facilitates the global adoption of its patented RFDS technology. Through KTL, Know Labs aims to work with corporations, universities, and research institutions under a structured licensing framework. The company indicates that this framework is intended to allow partners to develop applications using its RFDS platform while protecting those developments from counterfeiting and unauthorized use.

The KTL division is described as using an extensive intellectual property portfolio and a proprietary e-RFDS© digital watermark. Know Labs presents KTL as a way to make its platform technology available for medical diagnostics, industrial applications, and other areas, while maintaining protection of its inventions and trade secrets. The company has stated that, with KTL formally launched, it is open to licensing the intellectual property associated with its RFDS platform.

Intellectual Property Focus

Know Labs reports that a foundational aspect of its focus since inception has been the protection of its innovation through patent filings and the guarding of trade secrets. The company has disclosed that an independent third-party analysis by PatSnap evaluated its patent portfolio in certain categories of medical diagnostics and industrial process control. According to Know Labs, that analysis reported that its patent portfolio ranks highly in those categories. The company also notes that its trade secret portfolio, codified through the Tangibly trade secret platform, is considered by management to be a key component of its overall intellectual property strategy.

Know Labs has indicated that its total number of issued, pending, and in-process patents has changed over time as it combines provisional patents into utility patents and abandons pending patents it deems less important. It has also stated that both its patents and trade secrets are expected to grow in number as innovation continues. The company describes its intellectual property as designed both to protect its own inventions and to support collaboration with potential partners.

Trading Status and Listings Context

During the period covered by the referenced news releases, Know Labs common shares were quoted on the OTCQB Venture Market under the ticker symbol KNWN, with the temporary suffix "D" applied for a limited period in connection with a reverse stock split. The company described the OTCQB as a market for U.S. and international companies in the entrepreneurial and development stage, with eligibility requirements that include current financial reporting, a minimum bid price test, and annual verification and certification.

Know Labs also announced that staff of NYSE Regulation had withdrawn a prior delisting determination and would lift a trading suspension of the company’s common stock on the NYSE American, with trading expected to resume under the symbol KNW. According to the company, this decision followed a determination that its common stock was trading above the low selling price threshold in the NYSE American Company Guide. At the same time, Know Labs disclosed that it remained subject to a previously accepted plan to regain compliance with the NYSE American’s continued listing standards and that there was no assurance it would be able to meet those standards by the target date.

Applications and Regulatory Considerations

In its public statements, Know Labs highlights that its RFDS platform is intended to be adaptable to multiple form factors and use cases. The company has identified non-invasive glucose monitoring as one of its first expected applications. It emphasizes that this device will require FDA clearance before commercialization in the United States. Know Labs also notes that other products developed through its KTL program may not require prior FDA approval, depending on their specific use cases and regulatory pathways.

Because the company’s technology is described as a platform, Know Labs presents its RFDS approach as potentially applicable to a range of analytes and industries. It states that its patent and trade secret portfolios are structured to cover both core technology and various applications, and that it seeks to collaborate with partners in medical diagnostics, industrial process control, and other areas through licensing arrangements.

Business Model Orientation

Based on its public disclosures, Know Labs’ business orientation centers on the development, protection, and licensing of RFDS-based sensor technology. The company emphasizes intellectual property as a central asset, with patents and trade secrets supporting both its own product development efforts and its KTL licensing activities. It positions its initial product plans around non-invasive glucose monitoring while also indicating interest in broader medical and industrial applications through third-party collaborations.